← Back to Analyst Consensus 
ELDN Buy
Eledon Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 18, 2026 (23 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jul 21, 2026 | Rodman & Renshaw | initiate | — → Buy | — | 40% |
| Nov 18, 2025 | Guggenheim | maintain | Buy → Buy | $8 | 52% |
| Sep 2, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Jul 25, 2025 | Craig-Hallum | initiate | — → Buy | $12 | 54% |
| Nov 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $16 | 44% |
| Jun 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $16 | 44% |
| May 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $16 | 44% |
| May 7, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $16 | 44% |
| Mar 22, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Nov 13, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Oct 24, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $13 | 44% |
| Sep 27, 2023 | Noble Capital Markets | initiate | — → Outperform | $10 | 63% |
| Aug 22, 2023 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $9 | 50% |
| May 26, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Jun 1, 2022 | SVB Leerink | maintain | — → Outperform | $26 | — |
| Nov 24, 2021 | HC Wainwright & Co. | maintain | — → Buy | $25 | 44% |
| Apr 27, 2021 | SVB Leerink | maintain | — → Outperform | $33 | — |
| Mar 23, 2021 | Cantor Fitzgerald | initiate | — → Overweight | $25 | 50% |
| Feb 8, 2021 | SVB Leerink | initiate | — → Outperform | $34 | — |
Price Target Trend
Apr 23, 2026 Oct 26, 2026
EPS Estimates
0y —
+1q —
0q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days